Currently, Novo-Nordisk A/S has begun using Claude to draft clinical study reports, with each report potentially reaching hundreds of pages. Relevant authorities revealed that the use of AI tools has significantly shortened the drafting time from about 15 weeks to less than 10 minutes, and the company's annual expenditure on Claude is less than the salary of a single writer.
The cost for a year is less than the salary of one employee! $Novo-Nordisk A/S (NVO.US)$AI has been introduced into the drafting of drug regulatory documents, achieving significant results.
According to media reports, last year, the Danish pharmaceutical giant Novo-Nordisk A/S began testing Anthropic's Claude 3.5 Sonnet model. The director of Global Strategy for AI usage, Waheed Jowiya, found that the number of errors had significantly decreased. Currently, Novo-Nordisk A/S has started using Claude to draft clinical research reports, each of which can be hundreds of pages long.
For many years, Novo-Nordisk A/S has been testing AI chatbots, including OpenAI's ChatGPT and Meta's Llama, hoping to utilize these technologies to assist in writing drug approval documents submitted to regulatory Institutions.
However, Industries such as pharmaceuticals and Insurance, which are strictly regulated, have always taken a cautious approach towards using generative AI to handle legally sensitive documents. The company's head of technology strategy, Louise Lind Skov, stated that early technologies are prone to errors, and sometimes correcting AI mistakes is more time-consuming than rewriting from scratch.
It is reported that Novo-Nordisk A/S has adopted a common method to reduce AI error rates: retrieval-augmented generation (RAG). For example, when Claude generated a clinical definition of obesity that a human expert deemed good, the human would instruct Claude to reuse that description in any future documents about obesity trials.
Skov revealed that this practice has greatly shortened the document drafting time from about 15 weeks to less than 10 minutes. Previously, these documents required the participation of more than 50 writers, but now only 3 human writers can complete them with the help of Claude.
Moreover, Novo-Nordisk A/S spends less on Claude each year than the salary of a single writer. The company stated that it does not plan to cut any writing staff for now, but it intends to reduce new hiring and allocate the saved resources to recruitment in other departments.
Skov commented on this:
"This increase in efficiency means we can accomplish the same or even more work with fewer people."
"We moved AI rapidly from the experimental phase to the development phase, which is a rare fast progress in the pharmaceutical Industry."
Editor/danial
